Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in ...
EQS-News: Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention ...
Mainz Biomed supports Colorectal Cancer Awareness Month
Mainz Biomed (MYNZ) supports Colorectal Cancer Awareness Month in March. Detecting colorectal cancer in its early stages significantly improves ...
Mainz BioMed NV: Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the ...
Mainz Biomed Expands into Switzerland with labor team w
Partnership to Launch DNA-Based Colorectal Cancer Screening TestBERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE ...
Morningstar11d
Mainz Biomed Expands into Switzerland with labor team w
BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...
Mainz BioMed NV: Mainz Biomed Expands into Switzerland with labor team w
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...
manilatimes21d
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed” or the "Company”), a molecular genetics diagnostic company specializing in the ...
Hosted on MSN17d
Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation
Fintel reports that on February 14, 2025, Maxim Group initiated coverage of Mainz Biomed N.V. (NasdaqCM:MYNZ) with a Buy recommendation. Analyst Price Forecast Suggests 66.00% Downside As of November ...